Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Who remembers BRE-EX?

<< Previous

Bullboard Posts

Next >>

Comment by PTBaileyon Oct 07, 2021 11:35am

108 Views

Post# 33982365

RE:RE:RE:Who remembers BRE-EX?

SeeDonRun wrote:
Old Bre Ex. Big time scam where they tampered with the core samples and shot that stock up from a couple cents to over $200.

Any word of our results being tampered with and if so, when is the share price going to hit $500? Wake me up when it does so I can sell but until then, it's nothing like Bre Ex.

Some people don't do well with comparisons and then don't look bright.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario